A Phase 3 interventional study of Vildagliptin and Placebo in Type 2 Diabetes Mellitus, sponsored by Novartis. Completed at 66 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-02-23.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
To assess the efficacy and safety of vildagliptin add-on therapy to reduce HbA1c in patients with T2DM inadequately controlled by insulin, with or without concurrent metformin therapy.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.
This study's enrollment of 448 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Novartis is the lead sponsor of 703 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Vildagliptin
Drug: Placebo
HbA1c reduction
Time frame: 24 weeks
HbA1c reduction in subpopulation treated with insulin and with metformin
Time frame: 24 weeks
HbA1c reduction in subpopulation treated with insulin and without metformin
Time frame: 24 weeks
Reduction in FPG (overall and subpopulations)
Time frame: 24 weeks
Responder rates (overall and subpopulations)
Time frame: 24 weeks
Incidence of hypoglycemia and severe hypoglycemia (overall and subpopulations)
Time frame: 24 weeks
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis